Physician profile
Ilana E Lasner
NPI 1891180071
$4,185.67
in general payments reported to CMS, 2019-2025
28 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $267 · 2021: $528 · 2022: $525 · 2023: $1,118 · 2024: $445 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.03 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $753.58 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $291.12 | 2021-2025 | Emgality, Amyvid, Reyvow |
| Medtronic, INC. | $259.61 | 2021-2022 | |
| Biogen, INC. | $245.14 | 2022-2025 | Vumerity, Leqembi, Avonex |
| Lundbeck LLC | $164.32 | 2020-2025 | Vyepti |
| Pfizer INC. | $154.26 | 2023-2025 | |
| Eisai INC. | $145.67 | 2020-2023 | |
| Akcea Therapeutics, INC. | $125.00 | 2020 | |
| Amneal Pharmaceuticals LLC | $119.79 | 2023-2025 | Rytary, Crexont |
| Astrazeneca Pharmaceuticals LP | $92.89 | 2023-2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $80.48 | 2020-2023 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $63.92 | 2020-2023 | |
| Averitas Pharma INC. | $61.46 | 2023 | Qutenza |
| Biohaven Pharmaceutical Holding Company LTD. | $60.01 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $58.22 | 2024-2025 | |
| Abbott Laboratories | $55.86 | 2023-2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $53.90 | 2023-2024 | Austedo Xr |
| Csl Behring | $49.62 | 2020 | |
| Allergan, INC. | $46.47 | 2021-2022 | |
| Neurelis, INC. | $36.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.98 | 2024 | Jardiance |
| Cala Health, INC. | $19.63 | 2022 | |
| Ucb, INC. | $19.53 | 2021 | |
| Impel Pharmaceuticals INC. | $19.40 | 2023 | Trudhesa |
| Scilex Pharmaceuticals INC. | $17.80 | 2023 | Ztlido |
| Axsome Therapeutics, INC. | $17.49 | 2025 | Symbravo |
| Life Molecular Imaging LTD | $13.02 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilana Lasner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.